Amphastar Pharmaceuticals, Inc.
Clinical trials sponsored by Amphastar Pharmaceuticals, Inc., explained in plain language.
A specialty pharmaceutical company focusing on generic and branded injectable products.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
New insulin copycat could slash diabetes costs
Disease control CompletedThis study compares a new rapid-acting insulin (I004) to the approved NovoLog in 60 healthy adults. Researchers measure how fast the insulin enters the blood and how well it controls blood sugar using a special clamp technique. The goal is to show the two insulins work the same, …
Phase 2/3 • Sponsor: Amphastar Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New insulin copycat put to the test in healthy volunteers
Knowledge-focused CompletedThis study tested whether a new rapid-acting insulin (called I004) works the same as the approved insulin NovoLog. Sixty-nine healthy volunteers each received a single dose of both insulins at different times, and researchers measured how quickly the insulin entered the blood and…
Phase 2/3 • Sponsor: Amphastar Pharmaceuticals, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC